Catalyst Dossier · compiled by CeliA 🧫

CUMBERLAND PHARMACEUTICALS INC (CPIX)

Pharmaceutical Preparations · market cap $86M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-04

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-04Earningsimp 5/10
2027-01-15 (est.)Phase 2 · Ifetroban Sodiumimp 7/10

Pipeline

Asset	Phase	Indication
Intravenous ibuprofen	Phase 3	Pain
YM087	Phase 3	Hyponatremia
YM087 oral	Phase 3	Hyponatremia
Vancomycin	Phase 3	Staphylococcal Skin Infection
Caldolor	Phase 3	Burns
Vancomycin or antistaphylococcal penicillin	Phase 2	Infections, Gram-Positive Bacterial
Telavancin	Phase 3	Bacterial Pneumonia
Ibuprofen	Phase 3	Fever
Ifetroban	Phase 2	Duchenne Muscular Dystrophy Cardiomyopathy
conivaptan	Phase 3	Liver Cirrhosis
Ifetroban Injection	Phase 2	Hepatorenal Syndrome
Ifetroban Sodium	Phase 2	Idiopathic Pulmonary Fibrosis
Ifetroban Oral Capsule	Phase 2	Asthma, Aspirin-Induced
Atorvastatin injection	Phase 2	Hypercholesterolemia
Oral Ifetroban	Phase 2	Scleroderma, Diffuse
90 grams of Crystalline Lactulose	Phase 2	Colonoscopy Preparation
Ifetroban, Oral Capsule	Phase 2	Aspirin Exacerbated Respiratory Disease (AERD)
acetaminophen	Phase 3	Fever
Vancomycin, nafcillin, oxacillin, or cloxacillin	Phase 2	Gram-Positive Bacterial Infections
Full dose preparation	Phase 2	Colonoscopy Preparation

Price & technical context

3-month

+119.4%

6-month

+75.2%

12-month

+109.1%

52-wk range

$1.90–$7.13

vs 50-day MA

+35.3%

vs 200-day MA

+86.2%

Realized vol

95.1%

Max drawdown

-71.9%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for CPIX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.